2/14
09:15 am
blue
Adrenoleukodystrophy Drugs Market Projected to Reach USD 2.3 Billion by 2035, Boosted by Rising Investment in Biotechnology and Precision Medicine - Report by Transparency Market Research, Inc. [Yahoo! Finance]
Medium
Report
Adrenoleukodystrophy Drugs Market Projected to Reach USD 2.3 Billion by 2035, Boosted by Rising Investment in Biotechnology and Precision Medicine - Report by Transparency Market Research, Inc. [Yahoo! Finance]
1/30
09:34 am
blue
Latest Report by TMR Predicts Advanced Therapy Medicinal Products (ATMPs) Market to Surge with 16.6% CAGR, Expected to Reach US$ 245.1 Billion by 2034 | Uncover Future Trends in Healthcare [Yahoo! Finance]
Low
Report
Latest Report by TMR Predicts Advanced Therapy Medicinal Products (ATMPs) Market to Surge with 16.6% CAGR, Expected to Reach US$ 245.1 Billion by 2034 | Uncover Future Trends in Healthcare [Yahoo! Finance]
12/31
08:22 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Barclays PLC from $2.00 to $40.00. They now have an "overweight" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Barclays PLC from $2.00 to $40.00. They now have an "overweight" rating on the stock.
12/20
02:03 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/19
08:07 am
blue
March Biosciences Elects Peter Olagunju as Chair of Board of Directors [Yahoo! Finance]
Low
Report
March Biosciences Elects Peter Olagunju as Chair of Board of Directors [Yahoo! Finance]
12/12
02:03 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/8
12:30 pm
blue
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Medium
Report
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
12/7
12:00 pm
blue
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Medium
Report
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
12/4
04:05 pm
blue
bluebird bio Announces 1-for-20 Reverse Stock Split
High
Report
bluebird bio Announces 1-for-20 Reverse Stock Split
12/4
08:47 am
blue
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
High
Report
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
12/4
02:08 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/26
03:06 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/18
03:07 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.